Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from FSE

Rangers make UEFA fan plea and express Seville concerns after Europa League final issues

RANGERS have expressed their 'major concerns' over the treatment of supporters at the Europa League final and urged fans to come forward to raise…

The National (Scotland)

Rangers raise 'major concerns' over treatment of fans at Europa League Final

Rangers raise 'major concerns' over treatment of fans at Europa League Final

The club released a statement this afternoon following last week's Europa League final defeat at the hands of Eintracht Frankfurt.

Influential supporters' body FSE urges Rangers fans to have their say on Europa League Final issues

Influential supporters' body FSE urges Rangers fans to have their say on Europa League Final issues

Many who attended have complained about a lack of drinking water in scorching temperatures.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Future of European Super League discussed at key meeting

The private meeting, to discuss the future of football on the continent, was set to involve a representative of Andrea Agnelli’s office

The Independent UK

Uefa backs petition calling for the principles of sporting merit to be protected

Fans’ representatives met with the governing body a year on from the Super League’s collapse

The Independent UK

Novamind To Host MindMed Phase IIb Trial For LSD Based Drug For Anxiety Treatment

Novamind Inc. (OTCQB:NVMDF) (CSE:NM) (FSE:HN2) has been selected by Mind Medicine, Inc. (NASDAQ:MNMD) (NEO:MMED) to host a Phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults.

Novamind Stock Slightly Up On Grants Restricted Share Units

Novamind Inc. (OTCQB:NVMDF)(CSE:NM)(FSE:HN2) a mental health company specialized in psychedelic medicine, has granted an aggregate of 325,000 restricted share units effective March 11, 2022, to certain executives and employees of the company pursuant to its restricted share unit plan. The RSUs will vest in 25% intervals, every 6 months from…

inkl

Read news from The Economist, FT, and more,
with one subscription

Novamind To Conduct Phase II Psilocybin Trial For Major Depressive Disorder

Novamind To Conduct Phase II Psilocybin Trial For Major Depressive Disorder

Novamind Inc. (OTCQB:NVMDF) (CSE:NM)(FSE:HN2) will conduct a phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute. The company completed first patient randomization at its Draper, Utah research site.

High Tide Launches Cannabis Delivery On Demand At Select Alberta Canna Cabana Stores, Expands Ontario Retail Footprint

High Tide Launches Cannabis Delivery On Demand At Select Alberta Canna Cabana Stores, Expands Ontario Retail Footprint

High Tide Inc. (NASDAQ: HITI) (TSXV: HITI) (FSE: 2LYA) has launched its cannabis Delivery on Demand program at select Canna Cabana locations in Alberta.

High Tide's Canna Cabana Launches Cannabis Delivery On Demand

High Tide's Canna Cabana Launches Cannabis Delivery On Demand

High Tide Inc. (NASDAQ: HITI) (TSXV: HITI) (FSE: 2LYA) has launched cannabis Delivery on Demand in select Canna Cabana retail locations across Canada.

Novamind To Host Clinical Trial To Advance Ketamine Therapy For End-of-Life Patients

Novamind To Host Clinical Trial To Advance Ketamine Therapy For End-of-Life Patients

Mental health company specialized in psychedelic medicine Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE:HN2) has been selected by the Ketamine Research Foundation to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

UEFA Champions League

Eintracht Frankfurt

European Super League

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play